Cellectis Showcases Promising One-Time Gene Editing Approach for Severe Hypertriglyceridemia
Cellectis SA ( (FR:ALCLS) ) has provided an announcement. Cellectis has unveiled expanded preclinical data for.HEAL-101, an in vivo TALE base editing candidate targeting APOC3 for severe hypertriglyceridemia, at the European Society of Gene and Cell Therapy congress in Hamburg. The…